Nymox Pharmaceutical Corporation (NYMX)

Oncology Corporate Profile

Stock Performance

2.2500
0.0000

HQ Location

9900 Cavendish Boulevard
St. Laurent
Quebec, Canada H4M 2V2

Company Description

Nymox Pharmaceutical Corporation is engaged in the research and development of therapeutics and diagnostics, with a particular emphasis on products targeted for the unmet needs of the aging population. The Company_†_s new drug for benign prostatic hyperplasia (BPH) is in Phase 3 development in the U.S. and Europe. The Company_†_s candidate drug for prostate cancer is currently in Phase 2 testing in the U.S.

Website: http://www.nymox.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
NX-1207pro-apoptotic focal therapyProstate cancerII

View additional information on product candidates here »

Source


http://www.nymox.com

Recent News Headlines

Nymox Reports Additional Positive Results From Completed Fexapotide BPH Phase 3 Studies Showing Significant Early Response and First-Line Efficacy

11/29/2016 02:04 pm

[GlobeNewswire] - HASBROUCK HEIGHTS, N.J., Nov. 29, 2016-- Nymox Pharmaceutical Corporation is pleased to announce that new Phase 3 prospective randomized clinical trial results have confirmed that patients who received ...

Nymox Reports Successful New Phase 3 Long-Term Fexapotide Repeat Injection BPH Trial Results: Lasting Symptomatic Improvement Up To 6 Years After Single Repeated Treatment

10/11/2016 02:00 pm

[GlobeNewswire] - HASBROUCK HEIGHTS, N.J., Oct. 11, 2016-- Nymox Pharmaceutical Corporation is pleased to announce successful new study results from the long-term repeated injection group from the U.S. Phase 3 trials for ...

Nymox Reports Successful New Long-Term Fexapotide Placebo Crossover Study Results: Major Reduction in Incidence of Surgery

8/29/2016 03:02 pm

[at noodls] - NEWS RELEASE Contact: Paul Averback Nymox Pharmaceutical Corporation 800-93NYMOX www.nymox.com For Immediate Release: HASBROUCK HEIGHTS, NJ (August 24, 2016) Nymox Pharmaceutical Corporation (NASDAQ:NYMX) ...

Nymox's New Phase 3 Long-Term U.S. Results For Prostate Enlargement Drug Fexapotide Show

8/29/2016 03:02 pm

[at noodls] - NEWS RELEASE Contact: Paul Averback Nymox Pharmaceutical Corporation 800-93NYMOX www.nymox.com For Immediate Release: Dramatic Decrease in Prostate Cancer and Major Reduction in Need For BPH Prostate Surgery ...

Nymox's New Phase 3 Long-Term U.S. Results For Prostate Enlargement Drug Fexapotide Show

8/29/2016 02:03 pm

[GlobeNewswire] - Dramatic Decrease in Prostate Cancer and. Major Reduction in Need For BPH Prostate Surgery. HASBROUCK HEIGHTS, N.J., Aug. 29, 2016-- Nymox Pharmaceutical Corporation lead drug fexapotide which has been ...

Nymox Reports Successful New Long-Term Fexapotide Placebo Crossover Study Results: Major Reduction in Incidence of Surgery

8/24/2016 04:01 pm

[GlobeNewswire] - HASBROUCK HEIGHTS, N.J., Aug. 24, 2016-- Nymox Pharmaceutical Corporation is pleased to announce successful new study results from the long-term blinded placebo crossover group from the U.S. Phase 3 trials ...

Nymox reports 2Q loss

8/22/2016 02:01 pm

Nymox reports 2Q loss

8/22/2016 02:01 pm

Nymox Announces Prostate Drug Progress

8/17/2016 02:04 pm

[at noodls] - NEWS RELEASE Contact: Paul Averback Nymox Pharmaceutical Corporation 800-93NYMOX www.nymox.com For Immediate Release: HASBROUCK HEIGHTS, NJ (August 11, 2016) Nymox Pharmaceutical Corporation (NASDAQ:NYMX) ...

Nymox Announces Private Placements of $2.24 Million

8/17/2016 02:04 pm

[at noodls] - NEWS RELEASE Contact: Paul Averback Nymox Pharmaceutical Corporation 800-93NYMOX www.nymox.com For Immediate Release: HASBROUCK HEIGHTS, NJ (August 17, 2016) Nymox Pharmaceutical Corporation (NASDAQ:NYMX) ...

Nymox Announces Private Placements of $2.24 Million

8/17/2016 02:00 pm

[GlobeNewswire] - HASBROUCK HEIGHTS, N.J., Aug. 17, 2016-- Nymox Pharmaceutical Corporation is pleased to announce that it has recently closed private placements and other investments in the Company for a total of $2.24 ...

Nymox Announces Prostate Drug Progress

8/11/2016 02:02 pm

[GlobeNewswire] - HASBROUCK HEIGHTS, N.J., Aug. 11, 2016-- Nymox Pharmaceutical Corporation is pleased to announce major progress in the evidence for the safety and efficacy of fexapotide, the Company's Phase 3 drug in ...

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Nymox Pharmaceutical Corporation (NYMX)

8/11/2016 02:01 pm

[Accesswire] - NEW YORK, NY / ACCESSWIRE / August 11, 2016 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Nymox Pharmaceutical Corporation ("Nymox" ...

Nymox Pharmaceutical Corporation Investigated For Securities Fraud By Block & Leviton After Report Reveals Pervasive Misconduct By The Company

8/11/2016 09:00 am

[PR Newswire] - BOSTON, Aug. 11, 2016 /PRNewswire/ -- Block & Leviton LLP ( www.blockesq.com ), a securities litigation firm representing investors nationwide, is investigating whether Nymox Pharmaceutical Corporation ...

IMPORTANT INVESTOR NOTICE: Lundin Law PC Announces an Investigation of Nymox Pharmaceutical Corporation and Advises Investors with Losses to Contact the Firm

8/11/2016 02:02 am

[Business Wire] - Lundin Law PC announces that it is investigating claims against Nymox Pharmaceutical Corporation concerning possible violations of federal securities laws.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nymox Pharmaceutical Corporation - NYMX

8/10/2016 08:05 pm

[PR Newswire] - NEW YORK, Aug. 10, 2016 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Nymox Pharmaceutical Corporation ("Nymox" or the "Company") (NASDAQ: NYMX). ...